Novel Soluble Flt-1 Isoforms in Plasma and Cultured Placental Explants from Normotensive Pregnant and Preeclamptic Women

Placenta

Volumn 30, Issue 1, 2009, Pages 25-34

  Rajakumar, A ^a,b   Powers, R W ^a,b   Hubel, C A ^a,b   Shibata, E ^b   von Versen Hoynck F ^b   Plymire, D ^b   Jeyabalan, A ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Conditioned medium; Deglycosylation; Heparin agarose; New soluble Flt 1 variants; Plasma; Preeclampsia; sFlt 1; VEGF binding; Villous explant culture

Indexed keywords

AGAROSE; ANTIBODY; EPITOPE; HEPARIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1;

ADULT; ANTIGENICITY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTROPHOBLAST; DEGLYCOSYLATION; EXPLANT; FEMALE; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PLACENTA; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN PURIFICATION;

ADULT; BLOTTING, WESTERN; CELLS, CULTURED; CHORIONIC VILLI; CULTURE MEDIA, CONDITIONED; ENDOTHELIAL CELLS; FEMALE; GESTATIONAL AGE; HUMANS; MIDDLE AGED; ORGAN CULTURE TECHNIQUES; PRE-ECLAMPSIA; PREGNANCY; PROTEIN BINDING; PROTEIN ISOFORMS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 57649149233     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.placenta.2008.10.006     Document Type: Article

References (36)

1. Ilekis J.V., Reddy U.M., and Roberts J.M. Preeclampsia-a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 14 (2007) 508-523
2. Maynard S.E., Min J.Y., Merchan J., Lim K.H., Li J., Mondal S., et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 111 (2003) 649-658
3. Levine R.J., Maynard S.E., Qian C., Lim K.H., England L.J., Yu K.F., et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 350 (2004) 672-683
4. Ahmed A., Dunk C., Ahmad S., and Khaliq A. Regulation of placental vascular endothelial growth factor (VEGF) and placenta growth factor (PIGF) and soluble Flt-1 by oxygen-a review. Placenta 21 Suppl. A (2000) S16-S24
5. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90 (1993) 10705-10709
6. Clark D.E., Smith S.K., He Y., Day K.A., Licence D.R., Corps A.N., et al. A vascular endothelial growth factor antagonist is produced by the human placenta and released into the maternal circulation. Biol Reprod 59 (1998) 1540-1548
7. Li H., Gu B., Zhang Y., Lewis D.F., and Wang Y. Hypoxia-induced increase in soluble Flt-1 production correlates with enhanced oxidative stress in trophoblast cells from the human placenta. Placenta 26 (2005) 210-217
8. Nagamatsu T., Fujii T., Kusumi M., Zou L., Yamashita T., Osuga Y., et al. Cytotrophoblasts up-regulate soluble fms-like tyrosine kinase-1 expression under reduced oxygen: an implication for the placental vascular development and the pathophysiology of preeclampsia. Endocrinology 145 (2004) 4838-4845
9. Rajakumar A., Michael H.M., Rajakumar P.A., Shibata E., Hubel C.A., Karumanchi S.A., et al. Extra-placental expression of vascular endothelial growth factor receptor-1, (Flt-1) and soluble Flt-1 (sFlt-1), by peripheral blood mononuclear cells (PBMCs) in normotensive and preeclamptic pregnant women. Placenta 26 (2005) 563-573
10. Barleon B., Reusch P., Totzke F., Herzog C., Keck C., Martiny-Baron G., et al. Soluble VEGFR-1 secreted by endothelial cells and monocytes is present in human serum and plasma from healthy donors. Angiogenesis 4 (2001) 143-154
11. Clauss M., Weich H., Breier G., Knies U., Rockl W., Waltenberger J., et al. The vascular endothelial growth factor receptor Flt-1 mediates biological activities. Implications for a functional role of placenta growth factor in monocyte activation and chemotaxis. J Biol Chem 271 (1996) 17629-17634
12. Sela S., Itin A., Natanson-Yaron S., Greenfield C., Goldman-Wohl D., Yagel S., et al. A novel human-specific soluble vascular endothelial growth factor receptor 1: cell-type-specific splicing and implications to vascular endothelial growth factor homeostasis and preeclampsia. Circ Res 102 (2008) 1566-1574
13. Rajakumar A., Brandon H.M., Daftary A., Ness R., and Conrad K.P. Evidence for the functional activity of hypoxia-inducible transcription factors overexpressed in preeclamptic placentae. Placenta 25 (2004) 763-769
14. Soleymanlou N., Jurisica I., Nevo O., Ietta F., Zhang X., Zamudio S., et al. Molecular evidence of placental hypoxia in preeclampsia. J Clin Endocrinol Metab 90 (2005) 4299-4308
15. Gerber H.P., Condorelli F., Park J., and Ferrara N. Differential transcriptional regulation of the two vascular endothelial growth factor receptor genes. Flt-1, but not Flk-1/KDR, is up-regulated by hypoxia. J Biol Chem 272 (1997) 23659-23667
16. Ahmad S., and Ahmed A. Elevated placental soluble vascular endothelial growth factor receptor-1 inhibits angiogenesis in preeclampsia. Circ Res 95 (2004) 884-891
17. Nevo O., Soleymanlou N., Wu Y., Xu J., Kingdom J., Many A., et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 291 (2006) R1085-R1093
18. Shibuya M. Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct Funct 26 (2001) 25-35
19. Huckle W.R., and Roche R.I. Post-transcriptional control of expression of sFlt-1, an endogenous inhibitor of vascular endothelial growth factor. J Cell Biochem 93 (2004) 120-132
20. Thomas C., Andrews J.I., and Liu K.Z. Intronic polyadenylation signal sequences and alternate splicing generate human soluble Flt1 variants and regulate the abundance of soluble Flt1 in the placenta. FASEB J 21 (2007) 3885-3895
21. Roberts J.M., Pearson G., Cutler J., and Lindheimer M. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertension 41 (2003) 437-445
22. Roberts J.M., Bodnar L.M., Lain K.Y., Hubel C.A., Markovic N., Ness R.B., et al. Uric acid is as important as proteinuria in identifying fetal risk in women with gestational hypertension. Hypertension 46 (2005) 1263-1269
23. Rajakumar A., Doty K., Daftary A., Harger G., and Conrad K.P. Impaired oxygen-dependent reduction of HIF-1alpha and -2alpha proteins in pre-eclamptic placentae. Placenta 24 (2003) 199-208
24. Nelson D.M., Smith S.D., Furesz T.C., Sadovsky Y., Ganapathy V., Parvin C.A., et al. Hypoxia reduces expression and function of system A amino acid transporters in cultured term human trophoblasts. Am J Physiol, Cell Physiol 284 (2003) C310-C315
25. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996) 324-328
26. Margalit H., Fischer N., and Ben-Sasson S.A. Comparative analysis of structurally defined heparin binding sequences reveals a distinct spatial distribution of basic residues. J Biol Chem 268 (1993) 19228-19231
27. Park M., and Lee S.T. The fourth immunoglobulin-like loop in the extracellular domain of FLT-1, a VEGF receptor, includes a major heparin-binding site. Biochem Biophys Res Commun 264 (1999) 730-734
28. Boocock C.A., Charnock-Jones D.S., Sharkey A.M., McLaren J., Barker P.J., Wright K.A., et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst 87 (1995) 506-516
29. Gu Y., Lewis D.F., and Wang Y. Placental productions and expressions of soluble endoglin, soluble fms-like tyrosine kinase receptor-1, and placental growth factor in normal and preeclamptic pregnancies. J Clin Endocrinol Metab 93 (2008) 260-266
30. Wang Y., Gu Y., Zhang Y., Lewis D.F., Alexander J.S., and Granger D.N. Increased chymotrypsin-like protease (chymase) expression and activity in placentas from women with preeclampsia. Placenta 28 (2007) 263-269
31. Tanaka S.S., Togooka Y., Sato H., Seiki M., Tojo H., and Tachi C. Expression and localization of membrane type matrix metalloproteinase-1 (MT1-MMP) in trophoblast cells of cultured mouse blastocysts and ectoplacental cones. Placenta 19 (1998) 41-48
32. Makris A., Thornton C., Thompson J., Thomson S., Martin R., Ogle R., et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 71 (2007) 977-984
33. Gilbert J.S., Babcock S.A., and Granger J.P. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 50 (2007) 1142-1147
34. Lockwood C.J., Toti P., Arcuri F., Norwitz E., Funai E.F., Huang S.T., et al. Thrombin regulates soluble fms-like tyrosine kinase-1 (sFlt-1) expression in first trimester decidua: implications for preeclampsia. Am J Pathol 170 (2007) 1398-1405
35. Zhou C.C., Ahmad S., Mi T., Abbasi S., Xia L., Day M.C., et al. Autoantibody from women with preeclampsia induces soluble Fms-like tyrosine kinase-1 production via angiotensin type 1 receptor and calcineurin/nuclear factor of activated T-cells signaling. Hypertension 51 (2008) 1010-1019
36. Zhou C.C., Ahmad S., Mi T., Xia L., Abbasi S., Hewett P.W., et al. Angiotensin II induces soluble fms-Like tyrosine kinase-1 release via calcineurin signaling pathway in pregnancy. Circ Res 100 (2007) 88-95